Insights into T-cell exhaustion could improve cancer immunotherapies, Penn study finds

SITC accepting nominations for annual awards and the Academy of Immuno-Oncology

The Society for Immunotherapy of Cancer is taking nominations for the SITC Annual Awards and the Academy of Immuno-Oncology.

April 05, 2024

Vol.50 No.14

Clinical Roundup

UTSW discovers protective ‘acid wall’ formed by cancer cells

Cancer cells release a significantly more concentrated level of acid than previously known, forming an “acid wall” that could deter immune cells from attacking tumors, UT Southwestern Medical Center scientists showed in a study.

April 05, 2024

Vol.50 No.14

Drugs & Targets

FDA approves Abecma for earlier lines of treatment for MM

FDA approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial (The Cancer Letter, March 22, 2024).

April 05, 2024

Vol.50 No.14

Clinical Roundup

Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, to enhance immunotherapy effects against malignant tumors.

March 29, 2024

Vol.50 No.13

Clinical Roundup

Phase I study of CAR T-cell therapy shows clinical activity in glioblastoma

A phase I CAR T-cell therapy trial for the treatment of glioblastoma demonstrated promising clinical activity, according to research published in Nature Medicine.

March 15, 2024

Vol.50 No.11

Clinical Roundup

“Double life” of key immune protein reveals strategies for treating cancer and autoimmune diseases

Insights into the workings of PD-1 reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.

March 15, 2024

Vol.50 No.11

Insights into T-cell exhaustion could improve cancer immunotherapies, Penn study finds

YOU MAY BE INTERESTED IN

SITC accepting nominations for annual awards and the Academy of Immuno-Oncology

UTSW discovers protective ‘acid wall’ formed by cancer cells

FDA approves Abecma for earlier lines of treatment for MM

Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy

Phase I study of CAR T-cell therapy shows clinical activity in glioblastoma

“Double life” of key immune protein reveals strategies for treating cancer and autoimmune diseases

Renew today!

Subscriber content

Login